1-Benzylpiperazine and other Piperazine-based Derivatives

Novel Psychoactive Substances: Classification, Pharmacology and Toxicology

Volumn , Issue , 2013, Pages 179-209

  Gee, Paul ^a   Schep, Leo ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

1,3 trifluoromethylphenylpiperazine; 1 (3 chlorophenyl) piperazine; 1 (4 methoxyphenyl) piperazine; 1 benzylpiperazine; BZP; MCPP; MeOPP; Piperazines; TFMPP

Indexed keywords

EID: 84903800185     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-415816-0.00008-0     Document Type: Chapter

References (160)

1. DEA Office of domestic intelligence, Domestic strategic intelligence unit. BZP and TFMPP: chemicals used to mimic MDMA's effects. Microgram 2002;35: 123.
2. Couch RAF, Moore G Detection of 1-benzylpiperazine, a designer recreational drug marketed in New Zealand. Clin Exp Pharmacol Physiol 2004, 31. A227-A227.
3. de Boer D, Bosman IJ, Hidvégi E, Manzoni C, Benkö AA, dos Reys LJ, et al. Piperazine-like compounds: a new group of designer drugs-of-abuse on the European market. Forensic Sci Int 2001, 121:47-56.
4. Wikström M, Holmgren P, Ahlner J A2 (N-benzylpiperazine) a new drug of abuse in Sweden. J Anal Toxicol 2004, 28:67-70.
5. Joint formulary committee. British national formulary 59. London: Pharmaceutical Press; 2010.
6. Dessouky YM, Ismaiel SA Colorimetric determination of piperazine in pharmaceutical formulations. Analyst 1974, 99:482-486.
7. King LA, Nutt D Seizures in a night club. Lancet 2007, 370:220.
8. Nikolova I, Danchev N Piperazine based substances of abuse: a new party pills on Bulgarian drug market. Biotechnol Biotechnol Equip 2008, 22:652-655.
9. Baltzly R, Buck SJ, Lorz E, Schön W The Preparation of N-Mono-substituted and unsymmetrically disubstituted piperazines. J Am Chem Soc 1944, 66:263-266.
10. EMCDDA Report on the risk assessment of BZP in the framework of the council decision on new psychoactive substances 2009, EMCDDA, Lisbon, Available: [accessed 01.03.13].
11. Barrett PA, Caldwell AG, Walls LP Treatment of depression with n-benzylpiperazine 1968, United StatesSearch USPTO Assignment Database.
12. Bye C, Munro-Faure AD, Peck AW, Young PA A comparison of the effects of 1-benzylpiperazine and dexamphetamine on human performance tests. Eur J Clin Pharmacol 1973, 6:163-169.
13. Campbell H, Cline W, Evans M, Lloyd J, Peck AW Comparison of effects of dexamphetamine and 1-benzylpiperazine in former addicts. Eur J Clin Pharmacol 1973, 6:170-176.
14. Shulgin A, Shulgin A PiHKAL: a chemical love story 1991, Transform, Berkley, CA.
15. Feher L, Fonyo M, Magyar K Computer analysis of the pharmacokinetic parameters of EGYT-475, a new antidepressant agent. Pol J Pharmacol Pharm 1987, 39:167-171.
16. Fonyo M, Guttmann A, Magyar K Species differences in the in vitro metabolism of EGYT-475, a new antidepressant agent. Pol J Pharmacol Pharm 1987, 39:129-134.
17. Magyar K Pharmacokinetic aspects of the mode of action of Egyt-475, a new antidepressant agent. Pol J Pharmacol Pharm 1987, 39:107-112.
18. Malomvolgyi B, Tothfalusi L, Tekes K, Magyar K Comparison of serotonin agonistic and antagonistic activities of a new Antidepressant agent trelibet (Egyt-475) and its metabolite EGYT-2760 On isolated rat fundus. Acta Physiol Hung 1991, 78:201-209.
19. Szucks Z, Szentendrei T, Fekete MIK The effect of EGYT-475 (trelibet) and its metabolites on the potassium-stimulated H-3 noradrenaline release from cortical slices of rat-brain. Pol J Pharmacol Pharm 1987, 39:185-193.
20. Kast RE Trazodone generates m-CPP: in 2008 risks from m-CPP might outweigh benefits of trazodone. World J Biol Psychiatry 2009, 10:682-685.
21. Rotzinger S, Fang J, Baker GB Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources. Drug Metab Dispos 1998, 26:572-575.
22. Staack RF, Maurer HH Studies on the metabolism and the toxicological analysis of the nootropic drug fipexide in rat urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2004, 804:337-343.
23. Milne GWA Drugs: synonyms and propertie 2002, Ashgate Publishing, Aldershot, UK.
24. Guy C, Blay N, Rousset H, Fardeau V, Ollagnier M Fever caused by fipexide. Evaluation of the national pharmacovigilance survey. Therapie 1990, 45:429-431.
25. Durand F, Samuel D, Bernuau J, Saliba F, Pariente EA, Marion S, et al. Fipexide-induced fulminant hepatitis. Report of three cases with emergency liver transplantation. J Hepatol 1992, 15:144-146.
26. Keane PE, Strolin Benedetti M, Dow J The effect of niaprazine on the turnover of 5-hydroxytryptamine in the rat brain. Neuropharmacology 1982, 21:163-169.
27. Division of pharmacovigilance. Core safety profile niazaprine. Oslo, Norway: The Norwegian Medicines Agency Available: <>; 2009 [accessed 01.03.13]. http://www.legemiddelverket.no/upload/Coresafetyprofiles/CSPniaprazine200903.pdf.
28. Baron M, Elie M, Elie L An analysis of legal highs: do they contain what it says on the tin?. Drug Test Anal 2011, 3:576-581.
29. Vogels N, Brunt TM, Rigter S, van Dijk P, Vervaeke H, Niesink RJ Content of ecstasy in the Netherlands: 1993-2008. Addiction 2009, 104:2057-2066.
30. Baumann MH, Clark RD, Budzynski AG, Partilla JS, Blough BE, Rothman RB Effects of 'Legal X' piperazine analogs on dopamine and serotonin release in rat brain. Ann N Y Acad Sci 2004, 1025:189-197.
31. Baumann MH, Clark RD, Budzynski AG, Partilla JS, Blough BE, Rothman RB N-substituted piperazines abused by humans mimic the molecular mechanism of 3,4-methylenedioxymethamphetamine (MDMA, or 'Ecstasy'). Neuropsychopharmacology 2005, 30:550-560.
32. Bossong MG, Brunt TM, Van Dijk JP, Rigter SM, Hoek J, Goldschmidt HM, et al. mCPP: an undesired addition to the ecstasy market. J Psychopharmacol 2010, 24:1395-1401.
33. Antia U, Lee HS, Kydd RR, Tingle MD, Russell BR Pharmacokinetics of 'party pill' drug N-benzylpiperazine (BZP) in healthy human participants. Forensic Sci Int 2009, 186:63-67.
34. Antia U, Tingle MD, Russell BR In vivo interactions between BZP and TFMPP (party pill drugs). N Z Med J 2009, 122:29-38.
35. Antia U, Tingle MD, Russell BR Validation of an LC-MS method for the detection and quantification of BZP and TFMPP and their hydroxylated metabolites in human plasma and its application to the pharmacokinetic study of TFMPP in humans. J Forensic Sci 2010, 55:1311-1318.
36. Gee P, Gilbert M, Richardson S, Moore G, Paterson S, Graham P Toxicity from the recreational use of 1-benzylpiperazine. Clin Toxicol (Phila) 2008, 46:802-807.
37. Wilkins C, Girling M, Sweetsur P, Huckle T, Huakau J Legal party pill use in New Zealand: prevalence of use, availability, health harms and 'gateway effects' of benzylpiperazine (BZP) and triflourophenylmethylpiperazine (TFMPP) 2006, Centre for Social and Health Outcomes Research and Evaluation (SHORE), Auckland, Available: ; [accessed 01.03.13].
38. Pipes of piperazines: experience with cannabis, BZP, TFMPP (ID 14942). 2004. Available: <>. http://www.erowid.org/experiences/exp.php?ID=6138014942.
39. Surprisingly close to perfection: experience with Piperazines - mCPP , MeOPP (ID 57182). Available: <>; 2006 [accessed 04.03.13]. http://www.erowid.org/experiences/exp.php?ID=57182.
40. A burning nose: experience with piperazines - MeOPP (ID 61380). Available: <>; 2007 [accessed 04.03.13]. http://www.erowid.org/experiences/exp.php?ID=61380.
41. Wormwood (hash)+Piperazines+Methylphenidate (rectally)+Leonotis leonorus - Exp. Available: <>; 2005 [accessed 04.03.13]. http://www.bluelight.ru/vb/threads/189411.
42. Gijsman HJ, Van Gerven JM, Tieleman MC, Schoemaker RC, Pieters MS, Ferrari MD, et al. Pharmacokinetic and pharmacodynamic profile of oral and intravenous meta-chlorophenylpiperazine in healthy volunteers. J Clin Psychopharmacol 1998, 18:289-295.
43. Feuchtl A, Bagli M, Stephan R, Frahnert C, Kolsch H, Kuhn KU, et al. Pharmacokinetics of m-chlorophenylpiperazine after intravenous and oral administration in healthy male volunteers: implication for the pharmacodynamic profile. Pharmacopsychiatry 2004, 37:180-188.
44. Caccia S, Fong MH, Urso R Ionization constants and partition coefficients of 1-arylpiperazine derivatives. J Pharm Pharmacol 1985, 37:567-570.
45. Rotzinger S, Fang J, Coutts RT, Baker GB Human CYP2D6 and metabolism of m-chlorophenylpiperazine. Biol Psychiatry 1998, 44:1185-1191.
46. Staack RF, Fritschi G, Maurer HH Studies on the metabolism and toxicological detection of the new designer drug N-benzylpiperazine in urine using gas chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002, 773:35-46.
47. Staack RF, Paul LD, Springer D, Kraemer T, Maurer HH Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP). In vivo studies in Wistar and Dark Agouti rats as well as in vitro studies in human liver microsomes. Biochem Pharmacol 2004, 67:235-244.
48. Staack RF, Theobald DS, Paul LD, Springer D, Kraemer T, Maurer HH In vivo metabolism of the new designer drug 1-(4-methoxyphenyl)piperazine (MeOPP) in rat and identification of the human cytochrome P450 enzymes responsible for the major metabolic step. Xenobiotica 2004, 34:179-192.
49. Tsutsumi H, Katagi M, Miki A, Shima N, Kamata T, Nakajima K, et al. Metabolism and the urinary excretion profile of the recently scheduled designer drug N-benzylpiperazine (BZP) in the rat. J Anal Toxicol 2006, 30:38-43.
50. Staack RF, Fritschi G, Maurer HH New designer drug 1-(3-trifluoromethylphenyl) piperazine (TFMPP): gas chromatography/mass spectrometry and liquid chromatography/mass spectrometry studies on its phase I and II metabolism and on its toxicological detection in rat urine. J Mass Spectrom 2003, 38:971-981.
51. Tsutsumi H, Katagi M, Miki A, Shima N, Kamata T, Nakajima K, et al. Isolation, identification and excretion profile of the principal urinary metabolite of the recently banned designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP) in rats. Xenobiotica 2005, 35:107-116.
52. Mayol RF, Cole CA, Colson KE, Kerns EH Isolation and identification of the major urinary metabolite of m-chlorophenylpiperazine in the rat. Drug Metab Dispos 1994, 22:171-174.
53. Staack RF, Maurer HH Piperazine-derived designer drug 1-(3-chlorophenyl)piperazine (mCPP): GC-MS studies on its metabolism and its toxicological detection in rat urine including analytical differentiation from its precursor drugs trazodone and nefazodone. J Anal Toxicol 2003, 27:560-568.
54. Szoko E, Kalasz H, Kerecsen L, Magyar K Studies on serum binding of some drugs. Pol J Pharmacol Pharm 1987, 39:177-183.
55. Maurer HH, Kraemer T, Springer D, Staack RF Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types- A synopsis. Ther Drug Monit 2004, 26:127-131.
56. Antia U, Tingle MD, Russell BR Metabolic interactions with piperazine-based 'party pill' drugs. J Pharm Pharmacol 2009, 61:877-882.
57. Murphy M, Antia U, Chang HY, Han JY, Ibrahim U, Tingle MD, et al. Party pills and drug-drug interactions. N Z Med J 2009, 122:3564.
58. Sandson NB, Armstrong SC, Cozza KL An overview of psychotropic drug-drug interactions. Psychosomatics 2005, 46:464-494.
59. Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Ishida M, et al. Inhibition of trazodone metabolism by thioridazine in humans. Ther Drug Monit 1995, 17:333-335.
60. Mihara K, Otani K, Ishida M, Yasui N, Suzuki A, Ohkubo T, et al. Increases in plasma concentration of m-chlorophenylpiperazine, but not trazodone, with low-dose haloperidol. Ther Drug Monit 1997, 19:43-45.
61. Hollander E, Decaria C, Gully R, Nitescu A, Suckow RF, Gorman JM, et al. Effects of chronic fluoxetine treatment on behavioral and neuroendocrine responses to meta-chlorophenylpiperazine in obsessive-compulsive disorder. Psychiatry Res 1991, 36:1-17.
62. Staack RF, Paul LD, Schmid D, Roider G, Rolf B Proof of a 1-(3-chlorophenyl)piperazine (mCPP) intake: use as adulterant of cocaine resulting in drug-drug interactions?. J Chromatogr B Analyt Technol Biomed Life Sci 2007, 855:127-133.
63. Meririnne E, Kajos M, Kankaanpaa A, Seppala T Rewarding properties of 1-benzylpiperazine, a new drug of abuse, in rats. Basic Clin Pharmacol Toxicol 2006, 98:346-350.
64. Tekes K, Tothfalusi L, Malomvolgyi B, Herman F, Magyar K Studies on the biochemical-mode of action of EGYT-475, a new antidepressant. Pol J Pharmacol Pharm 1987, 39:203-211.
65. Nagai F, Nonaka R, Kamimura KSH The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain. Eur J Pharmacol 2007, 559:132-137.
66. Oberlander C, Euvrard C, Dumont C, Boissier JR Circling behavior induced by dopamine releasers and-or uptake inhibitors during degeneration of the nigrostriatal pathway. Eur J Pharmacol 1979, 60:163-170.
67. Magyar K, Fekete MIK, Tekes K, Torok TL The action of trelibet, a new antidepressive agent on [H-3] noradrenaline release from rabbit pulmonary artery. Eur J Pharmacol 1986, 130:219-227.
68. Yarosh HL, Katz EB, Coop A, Fantegrossi WE MDMA-like behavioral effects of N-substituted piperazines in the mouse. Pharmacol Biochem Behav 2007, 88:18-27.
69. Aitchison LK, Hughes RN Treatment of adolescent rats with 1-benzylpiperazine: a preliminary study of subsequent behavioral effects. Neurotoxicol Teratol 2006, 28:453-458.
70. Herndon JL, Pierson ME, Glennon RA Mechanistic investigation of the stimulus properties of 1-(3-trifluoromethylphenyl)piperazine. Pharmacol Biochem Behav 1992, 43:739-748.
71. Cunningham KA, Appel JB Possible 5-hydroxytryptamine 1 (5HT1) receptor involvement in the stimulus properties of 1-(m-trifluoromethylphenyl)piperazine (TFMPP). J Pharmacol Exp Ther 1986, 237:369-377.
72. Miranda F, Orozco G, Velazquez-Martinez DN Full substitution of the discriminative cue of a 5-HT(1A/1B/2C) agonist with the combined administration of a 5-HT(1B/2C) and a 5-HT(1A) agonist. Behav Pharmacol 2002, 13:303-311.
73. Auerbach SB, Kamalakannan N, Rutter JJ TFMPP and RU24969 enhance serotonin release from rat hippocampus. Eur J Pharmacol 1990, 190:51-57.
74. Berg KA, Harvey JA, Spampinato U, Clarke WP Physiological and therapeutic relevance of constitutive activity of 5-HT 2A and 5-HT 2C receptors for the treatment of depression. Prog Brain Res 2008, 172:287-304.
75. Conn PJ, Sanders-Bush E Relative efficacies of piperazines at the phosphoinositide hydrolysis-linked serotonergic (5-HT-2 and 5-HT-1c) receptors. J Pharmacol Exp Ther 1987, 242:552-777.
76. Grotewiel MS, Chu H, Sanders-Bush E m-chlorophenylpiperazine and m-trifluoromethylphenylpiperazine are partial agonists at cloned 5-HT2A receptors expressed in fibroblasts. J Pharmacol Exp Ther 1994, 271:1122-1126.
77. Appel JB, Callahan PM Involvement of 5-HT receptor subtypes in the discriminative stimulus properties of mescaline. Eur J Pharmacol 1989, 159:41-46.
78. Robertson DW, Bloomquist W, Wong DT, Cohen ML mCPP but not TFMPP is an antagonist at cardiac 5HT3 receptors. Life Sci 1992, 50:599-605.
79. Pettibone DJ, Williams M Serotonin-releasing effects of substituted piperazines in vitro. Biochem Pharmacol 1984, 33:1531-1535.
80. Gatch MB Discriminative stimulus effects of m-chlorophenylpiperazine as a model of the role of serotonin receptors in anxiety. Life Sci 2003, 73:1347-1367.
81. Rajkumar R, Pandey DK, Mahesh R, Radha R 1-(m-Chlorophenyl)piperazine induces depressogenic-like behaviour in rodents by stimulating the neuronal 5-HT(2A) receptors: proposal of a modified rodent antidepressant assay. Eur J Pharmacol 2009, 608:32-41.
82. Silverstone PH, Rue JE, Franklin M, Hallis K, Camplin G, Laver D, et al. The effects of administration of mCPP on psychological, cognitive, cardiovascular, hormonal and MHPG measurements in human volunteers. Int Clin Psychopharmacol 1994, 9:173-178.
83. Eriksson E, Engberg G, Bing O, Nissbrandt H Effects of mCPP on the extracellular concentrations of serotonin and dopamine in rat brain. Neuropsychopharmacology 1999, 20:287-296.
84. Kennett GA, Curzon G Evidence that mCPP may have behavioural effects mediated by central 5-HT1C receptors. Br J Pharmacol 1988, 94:137-147.
85. Kennett GA, Whitton P, Shah K, Curzon G Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists. Eur J Pharmacol 1989, 164:445-454.
86. Goodman WK, McDougle CJ, Price LH, Barr LC, Hills OF, Caplik JF, et al. m-Chlorophenylpiperazine in patients with obsessive-compulsive disorder: absence of symptom exacerbation. Biol Psychiatry 1995, 38:138-149.
87. Scherman D, Hamon M, Gozlan H, Henry JP, Lesage A, Masson M, et al. Molecular pharmacology of niaprazine. Prog Neuropsychopharmacol Biol Psychiatry 1988, 12:989-1001.
88. Lin JC, Bangs N, Lee H, Kydd RR, Russell BR Determining the subjective and physiological effects of BZP on human females. Psychopharmacology (Berl) 2009, 207:439-446.
89. Thompson I, Williams G, Caldwell B, Aldington S, Dickson S, Lucas N, et al. Randomised double-blind, placebo-controlled trial of the effects of the 'party pills' BZP/TFMPP alone and in combination with alcohol. J Psychopharmacol 2010, 24:1299-1308.
90. Campbell H, Peck AW, Lloyd J, Clane W, Evans M Comparison of effects of dexamphetamine and 1-benzylpiperazine in former addicts. Br J Pharmacol 1972, 44:P369-P370.
91. Jan RK, Lin JC, Lee H, Sheridan JL, Kydd RR, Kirk IJ, et al. Determining the subjective effects of TFMPP in human males. Psychopharmacology (Berl) 2010, 211:347-353.
92. Lin JC, Jan RK, Lee H, Jensen MA, Kydd RR, Russell BR Determining the subjective and physiological effects of BZP combined with TFMPP in human males. Psychopharmacology (Berl) 2011, 214:761-768.
93. Tancer M, Johanson CE Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP. Drug Alcohol Depend 2003, 72:33-44.
94. Tancer ME, Johanson CE The subjective effects of MDMA and mCPP in moderate MDMA users. Drug Alcohol Depend 2001, 65:97-101.
95. Charney DS, Woods SW, Goodman WK, Heninger GR Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology (Berl) 1987, 92:14-24.
96. Lawlor BA, Sunderland T, Mellow AM, Hill JL, Molchan SE, Murphy DL Hyperresponsivity to the serotonin agonist m-chlorophenylpiperazine in Alzheimer's disease. A controlled study. Arch Gen Psychiatry 1989, 46:542-549.
97. Mueller EA, Murphy DL, Sunderland T Neuroendocrine effects of M-chlorophenylpiperazine, a serotonin agonist, in humans. J Clin Endocrinol Metab 1985, 61:1179-1184.
98. Murphy DL, Mueller EA, Hill JL, Tolliver TJ, Jacobsen FM Comparative anxiogenic, neuroendocrine, and other physiologic effects of m-chlorophenylpiperazine given intravenously or orally to healthy volunteers. Psychopharmacology (Berl) 1989, 98:275-282.
99. Butler RA, Sheridan JL Highs and lows: patterns of use, positive and negative effects of benzylpiperazine-containing party pills (BZP-party pills) amongst young people in New Zealand. Harm Reduct J 2007, 4:18.
100. Nicholson TC Prevalence of use, epidemiology and toxicity of 'herbal party pills' among those presenting to the emergency department. Emerg Med Australas 2006, 18:180-184.
101. Wilkins C, Girling M, Sweetsur P The prevalence of use, dependency and harms of legal 'party pills' containing benzylpiperazine (BZP) and trifluorophenylmethylpiperazine (TFMPP) in New Zealand. J Subst Use 2007, 12:213-224.
102. Wilkins C, Sweetsur P Differences in harm from legal BZP/TFMPP party pills between North Island and South Island users in New Zealand: a case of effective industry self-regulation?. Int J Drug Policy 2010, 21:86-90.
103. Wilkins C, Sweetsur P, Girling M Patterns of benzylpiperazine/trifluoromethylphenylpiperazine party pill use and adverse effects in a population sample in New Zealand. Drug Alcohol Rev 2008, 27:633-639.
104. Iqbal N, Asnis GM, Wetzler S, Kahn RS, Kay SR, van Praag HM The MCPP challenge test in schizophrenia: hormonal and behavioral responses. Biol Psychiatry 1991, 30:770-778.
105. Gross-Isseroff R, Cohen R, Sasson Y, Voet H, Zohar J Serotonergic dissection of obsessive compulsive symptoms: a challenge study with m-chlorophenylpiperazine and sumatriptan. Neuropsychobiology 2004, 50:200-205.
106. Hollander E, DeCaria CM, Nitescu A, Gully R, Suckow RF, Cooper TB, et al. Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers. Arch Gen Psychiatry 1992, 49:21-28.
107. Hollander E, Fay M, Cohen B, Campeas R, Gorman JM, Liebowitz MR Serotonergic and noradrenergic sensitivity in obsessive-compulsive disorder: behavioral findings. Am J Psychiatry 1988, 145:1015-1017.
108. Pigott TA, Hill JL, Grady TA, L'Heureux F, Bernstein S, Rubenstein CS, et al. A comparison of the behavioral effects of oral versus intravenous mCPP administration in OCD patients and the effect of metergoline prior to i.v. mCPP. Biol Psychiatry 1993, 33:3-14.
109. Zohar J, Mueller EA, Insel TR, Zohar-Kadouch RC, Murphy DL Serotonergic responsivity in obsessive-compulsive disorder. Comparison of patients and healthy controls. Arch Gen Psychiatry 1987, 44:946-951.
110. Schep LJ, Slaughter RJ, Vale JA, Beasley DM, Gee P The clinical toxicology of the designer 'party pills' benzylpiperazine and trifluoromethylphenylpiperazine. Clin Toxicol (Phila) 2011, 49:131-141.
111. Gee P, Jerram T, Bowie D Multiorgan failure from 1-benzylpiperazine ingestion - legal high or lethal high?. Clin Toxicol (Phila) 2010, 48:230-233.
112. Gee P, Richardson S Researching the toxicity of party pills. Nurs N Z 2005, 11:12-13.
113. Wood DM, Dargan PI, Button J, Holt DW, Ovaska H, Ramsey J, et al. Collapse, reported seizure - and an unexpected pill. Lancet 2007, 369. 1490-1490.
114. Austin H, Monasterio E Acute psychosis following ingestion of 'Rapture'. Australas Psychiatry 2004, 12:406-408.
115. Theron Y, Jansen K, Miles J Benzylpiperizine-based party pills' impact on the Auckland city hospital emergency department overdose database (2002-2004) compared with ecstasy (MDMA or methylene dioxymethamphetamine), gamma hydroxybutyrate (GHB), amphetamines, cocaine, and alcohol. N Z Med J 2007, 120:U2416.
116. Wood DM, Button J, Lidder S, Ramsey J, Holt DW, Dargan PI Dissociative and sympathomimetic toxicity associated with recreational use of 1-(3-trifluoromethylphenyl) piperazine (TFMPP) and 1-benzylpiperzine (BZP). J Med Toxicol 2008, 4:254-257.
117. Alansari M, Hamilton D Nephrotoxicity of BZP-based herbal party pills: a New Zealand case report. N Z Med J 2006, 119:U1959.
118. Harnett MA Piperazine-based party drugs: case series of 73 poisonings [Conference abstract]. Clin Toxicol (Phila) 2007, 45:373.
119. Poon WT, Lai CF, Lui MC, Chan AY, Mak TW Piperazines: a new class of drug of abuse has landed in Hong Kong. Hong Kong Med J 2010, 16:76-77.
120. Elliott S, Smith C Investigation of the first deaths in the United Kingdom involving the detection and quantitation of the piperazines BZP and 3-TFMPP. J Anal Toxicol 2008, 32:172-177.
121. Staack RF, Maurer HH Metabolism of designer drugs of abuse. Curr Drug Metab 2005, 6:259-274.
122. Gee P, Richardson S, Woltersdorf W, Moore G Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christchurch, New Zealand. N Z Med J 2005, 118:U1784.
123. Lynton RC, Albertson TE Medical toxicology 2004, Lippincott Williams and Wilkins, Philadelphia. R.C. Dart (Ed.).
124. Nie Z, Yuan X, Madamba SG, Siggins GR Ethanol decreases glutamatergic synaptic transmission in rat nucleus accumbens in vitro: naloxone reversal. J Pharmacol Exp Ther 1993, 266:1705-1712.
125. Sanna E, Serra M, Cossu A, Colombo G, Follesa P, Cuccheddu T, et al. Chronic ethanol intoxication induces differential effects on GABAA and NMDA receptor function in the rat brain. Alcohol Clin Exp Res 1993, 17:115-123.
126. Button J, Wood DM, Dargan PI, Ovaska H, Jones AL, Ramsey J, et al. A gas chromatography mass-spectrometric method for the quantitative analysis of the recreational drug n-benzylpiperazine in serum. Ther Drug Monit 2007, 29:496.
127. Klaassen T, Pian KLH, Westenberg HGM, den Boer JA, van Praag HM Serotonin syndrome after challenge with the 5-HT agonist meta-chlorophenylpiperazine. Psychiatry Res 1998, 79:207-212.
128. Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM The hunter serotonin toxicity criteria: simple and accurate diagnostic decision rules for serotonin toxicity. Q J M 2003, 96:635-642.
129. Isbister GK, Buckley NA, Whyte IM Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust 2007, 187:361-365.
130. Balmelli C, Kupferschmidt H, Rentsch K, Schneemann M [Fatal brain oedema after ingestion of ecstasy and benzylpiperazine] German. Dtsch Med Wochenschr 2001, 126:809-811.
131. Hartung TK, Schofield E, Short AI, Parr MJ, Henry JA Hyponatraemic states following 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') ingestion. Q J M 2002, 95:431-437.
132. Berney-Meyer L, Putt T, Schollum J, Walker R Nephrotoxicity of recreational party drugs. Nephrology (Carlton) 2012, 17:99-103.
133. Cole M Poison in party pills is too much to swallow. Nature 2011, 474:253.
134. Schep LJ, Slaughter RJ, Beasley DMG The clinical toxicology of metamfetamine. Clin Toxicol (Phila) 2010, 48:675-694.
135. Mohandas A, Vecchio D A case report of Benzylpiperazine induced new onset affective symptoms in a patient with schizophrenia. Eur Psychiatry 2008, 23:S315-S316.
136. Suzuki A, Nakamura K, Sekine Y, Minabe Y, Takei N, Suzuki K, et al. An association study between catechol-O-methyl transferase gene polymorphism and methamphetamine psychotic disorder. Psychiat Genet 2006, 16:133-138.
137. EMCDDA. Europol-EMCDDA Joint report on a new psychoactive substance: 1-(3-chlorophenyl) piperazine (mCPP). Available: <>; 2005 [accessed 04.03.03]. http://www.emcdda.europa.eu/attachements.cfm/att_132213_EN_Final%20Joint%20Report%20mCPP.pdf.
138. Kovaleva J, Devuyst E, De Paepe P, Verstraete A Acute chlorophenylpiperazine overdose: a case report and review of the literature. Ther Drug Monit 2008, 30:394-398.
139. Bailey B Gastrointestinal decontamination triangle. Clin Toxicol (Phila) 2005, 43:59-60.
140. Shah AS, Eddleston M Should phenytoin or barbiturates be used as second-line anticonvulsant therapy for toxicological seizures?. Clin. Toxicol. (Phila) 2010, 48:800-805.
141. Callaway CW, Clark RF Hyperthermia in psychostimulant overdose. Ann Emerg Med 1994, 24:68-76.
142. Rusyniak DE, Sprague JE Hyperthermic syndromes induced by toxins. Clin Lab Med 2006, 26:165-184. ix.
143. Greene SL, Kerr F, Braitberg G Review article: amphetamines and related drugs of abuse. Emerg Med Australas 2008, 20:391-402.
144. Sun-Edelstein C, Tepper SJ, Shapiro RE Drug-induced serotonin syndrome: a review. Expert Opin Drug Saf 2008, 7:587-596.
145. Hall AP, Henry JA Acute toxic effects of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. Br J Anaesth 2006, 96:678-685.
146. Isbister GK, Buckley NA The pathophysiology of serotonin toxicity in animals and humans: implications for diagnosis and treatment. Clin Neuropharmacol 2005, 28:205-214.
147. Zietse R, van der Lubbe N, Hoorn EJ Current and future treatment options in SIADH. NDT Plus 2009, 2:iii12-iii19.
148. Bosch X, Poch E, Grau JM Current concepts: rhabdomyolysis and acute kidney injury. N Engl J Med 2009, 361:62-72.
149. Elliott S Current awareness of piperazines: pharmacology and toxicology. Drug Test Anal 2011, 3:430-438.
150. Bellingham SJ. Findings of Inquest; Coronial Court at Christchurch, New Zealand. 15 December 2009. 2011; COR REF: CSU-2008-WHG-000273.
151. Smith-Kielland A, Olsen KM, Christophersen AS False-positive results with Emit II amphetamine/methamphetamine assay in users of common psychotropic drugs. Clin. Chem. 1995, 41:951-952.
152. Capela JP, Carmo H, Remiao F, Bastos ML, Meisel A, Carvalho F Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol Neurobiol 2009, 39:210-271.
153. Fatovich DM, McCoubrie DL, Song SJ, Rosen DM, Lawn ND, Daly FF Brain abnormalities detected on magnetic resonance imaging of amphetamine users presenting to an emergency department: a pilot study. Med J Aust 2010, 193:266-268.
154. Berman S, O'Neill J, Fears S, Bartzokis G, London ED Abuse of amphetamines and structural abnormalities in the brain. Ann N Y Acad Sci 2008, 1141:195-220.
155. Wise RA Roles for nigrostriatal-not just mesocorticolimbic-dopamine in reward and addiction. Trends Neurosci 2009, 32:517-524.
156. Johnstone AC, Lea RA, Brennan KA, Schenk S, Kennedy MA, Fitzmaurice PS Benzylpiperazine: a drug of abuse?. J Psychopharmacol 2007, 21:888-894.
157. Fantegrossi WE, Winger G, Woods JH, Woolverton WL, Coop A Reinforcing and discriminative stimulus effects of 1-benzylpiperazine and trifluoromethylphenylpiperazine in rhesus monkeys. Drug Alcohol Depend 2005, 77:161-168.
158. Brennan K, Johnstone A, Fitzmaurice P, Lea R, Schenk S Chronic benzylpiperazine (BZP) exposure produces behavioral sensitization and cross-sensitization to methamphetamine (MA). Drug Alcohol Depend 2007, 88:204-213.
159. Kim MT, Hill MN Validity of self-report of illicit drug use in young hypertensive urban African American males. Addict Behav 2003, 28:795-802.
160. Lee MO, Vivier PM, Diercks DB Is the self-report of recent cocaine or methamphetamine use reliable in illicit stimulant drug users who present to the emergency department with chest pain?. J Emerg Med 2009, 37:237-240.